growth hormone-releasing peptide-2 (KP 102)

stimulates growth hormone secretion

Also Known As:

KP 102; Ala-beta-Nal-Ala-Trp-Phe-Lys-NH2; D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; GHRP-2; KP-102; alanyl-(2-naphthyl)alanyl-alanyl-tryptophyl-phenylalanyl-lysinamide; pralmorelin

Networked: 58 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - growth hormone-releasing peptide-2: 58

Experts

1.	Bowers, Cyril Y: 6 articles (09/2015 - 03/2002)
2.	Kageyama, Kazunori: 4 articles (10/2018 - 08/2008)
3.	Sakihara, Satoru: 4 articles (10/2018 - 08/2008)
4.	Van den Berghe, Greet: 4 articles (12/2005 - 03/2002)
5.	Terui, Ken: 3 articles (10/2018 - 08/2008)
6.	Balasubramaniam, Ambikaipakan: 3 articles (04/2012 - 01/2009)
7.	Friend, Lou Ann: 3 articles (04/2012 - 01/2009)
8.	James, J Howard: 3 articles (04/2012 - 01/2009)
9.	Joshi, Rashika: 3 articles (04/2012 - 01/2009)
10.	Suda, Toshihiro: 3 articles (11/2009 - 08/2008)

Related Diseases

1.	Reperfusion Injury 08/01/2006 - "In conclusion, KP-102 improved cardiac function in rat isolated hearts subjected to ischemia/reperfusion injury, which is independent of GH secretion." 08/01/2006 - "In the present study, we investigated the direct cardiac effects of KP-102 with regard to ischemia/reperfusion injury by using isolated rat hearts. " 08/01/2006 - "KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts."
2.	Neoplasms (Cancer) 11/07/2008 - "These data suggest that GHRP-2 may improve the efficacy of therapy and the quality of life of cancer patients thank to the amelioration of their nutritional state." 01/01/2022 - "The regression slopes between tumor height and peak GH response to GHRP-2 significantly differed between overweight patients and non-overweight individuals, as determined by analysis of covariance (P = 0.040). " 01/01/2022 - "Body mass index (β = -0.210, P = 0.007), free thyroxine (β = 0.440, P < 0.001), and tumor height (β = -0.254, P < 0.001) were significant variables for determining the peak GH response to GHRP-2 in multiple regression analyses. " 02/01/1998 - "In culture, four of the tumors exhibited strong responses to GHRP-2 in terms of both phosphatidylinositol (PI) hydrolysis and GH secretion, but two were resistant. " 11/27/2009 - "GHRP-2 may stimulate ACTH release directly via GHRP receptor type 1a in ACTH-producing tumors. "
3.	Hypoglycemia (Reactive Hypoglycemia) 09/01/2015 - "GHRP-2 increased the feeling of hunger and food intake, decreased early satiety and improved hypoglycemia. " 09/01/2015 - "One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient." 01/01/2010 - "Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2."
4.	Cachexia 11/07/2008 - "For the first time, we demonstrated that the addition of GHRP-2 to cytotoxic therapy with 5-FU improved appetite in tumour-bearing mice with anorexia/cachexia syndrome in early stage. "
5.	Anorexia 11/07/2008 - "For the first time, we demonstrated that the addition of GHRP-2 to cytotoxic therapy with 5-FU improved appetite in tumour-bearing mice with anorexia/cachexia syndrome in early stage. "

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	growth hormone-releasing peptide-2 (KP 102)
3.	Insulin (Novolin)
4.	Hormones (Hormone)
5.	Cysteamine (Mercaptamine)
6.	bis(maltolato)oxovanadium(IV)
7.	somatotropin releasing hormone receptor
8.	Ghrelin
9.	Hydrocortisone (Cortisol)
10.	Adrenocorticotropic Hormone (ACTH)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Subcutaneous Injections
4.	Anesthesia
5.	Oral Administration